Efficacy and Tolerability of Nebivolol Compared With Carvedilol in Patients With Coronary Artery Disease and Stage I or II Hypertension

NCT00673075 Phase 4 COMPLETED Results posted

This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.

Details

Lead sponsor	Forest Laboratories
Phase	Phase 4
Status	COMPLETED
Enrolment	39
Start date	2008-05

Conditions

• Hypertension
• Coronary Artery Disease

Interventions

• Nebivolol
• Carvedilol

Primary outcomes

• Peripheral Diastolic Blood Pressure (DBP) — 18 weeks post initiation of randomized treatment
  Peripheral diastolic blood pressure (DBP) at post-baseline (visit 13, week 18)

Countries

United States